

Review article

Extracellular matrix hydrogel therapies: *in vivo* applications and development

Martin T. Spang, Karen L. Christman

PII: S1742-7061(17)30785-7
DOI: https://doi.org/10.1016/j.actbio.2017.12.019
Reference: ACTBIO 5231

To appear in: *Acta Biomaterialia*

Received Date: 1 September 2017
Revised Date: 9 November 2017
Accepted Date: 15 December 2017

Please cite this article as: Spang, M.T., Christman, K.L., Extracellular matrix hydrogel therapies: *in vivo* applications and development, *Acta Biomaterialia* (2017), doi: https://doi.org/10.1016/j.actbio.2017.12.019

Extracellular matrix hydrogel therapies: *in vivo* applications and development

Martin T. Spang, Karen L. Christman*

Department of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA 92037, USA

*Corresponding author at: Dr. Karen L. Christman, Department of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California, San Diego, 2880 Torrey Pines Scenic Drive, La Jolla, California, 92037. E-mail: christman@eng.ucsd.edu; Office Phone**:** 858-822-7863; Fax: 858-534-5722

Abstract

Decellularized extracellular matrix (ECM) has been widely used for tissue engineering applications and is becoming increasingly versatile as it can take many forms, including patches, powders, and hydrogels. Following additional processing, decellularized ECM can form an inducible hydrogel that can be injected, providing for new minimally-invasive procedure opportunities. ECM hydrogels have been derived from numerous tissue sources and applied to treat many disease models, such as ischemic injuries and organ regeneration or replacement. This review will focus on *in vivo* applications of ECM hydrogels and functional outcomes in disease models, as well as discuss considerations for clinical translation.

Statement of Significance